AgomAb Therapeutics (NASDAQ:AGMB) Director David Epstein Purchases 10,000 Shares of Company Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 10,000 shares of AgomAb Therapeutics stock in a transaction that occurred on Wednesday, October 21st. The shares were bought at an average price of $8.88 per share, for a total transaction of $88,800.00. Following the transaction, the director owned 25,000 shares of the company’s stock, valued at $222,000. This represents a 66.67% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

AgomAb Therapeutics Price Performance

NASDAQ AGMB opened at $9.26 on Friday. The stock’s fifty day moving average is $11.60 and its two-hundred day moving average is $11.77. AgomAb Therapeutics NV has a fifty-two week low of $7.92 and a fifty-two week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. On average, research analysts anticipate that AgomAb Therapeutics NV will post -1.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AGMB shares. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Johnson Rice reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.